A recent systematic review of preclinical data demonstrated that VSV-IFNβ consistently reduces neurotoxicity while maintaining robust antitumor activity across various cancer models, including melanoma, hepatocellular carcinoma, and multiple myeloma [57]. The gene discussed is IFNB1; the disease is plasma cell myeloma.